A Subanalysis of the Phase 3 MONARCH 3 Study of Abemaciclib as Initial Therapy for HR-Positive, HER2-Negative Advanced Breast Cancer

2021 Year in Review - Breast Cancer - Breast Cancer

A subpopulation analysis of MONARCH 3, where a placebo-controlled phase 3 study of abemaciclib plus nonsteroidal aromatase inhibitors for advanced breast cancer, was used to study the progression-free survival (PFS) of abemaciclib as initial therapy in advanced breast cancer.1

Postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced breast cancer who had not received previous systemic therapy in the advanced illness setting were eligible. Abemaciclib or placebo (150 mg) plus either 1 mg anastrozole or 2.5 mg letrozole (physician’s option) were given to patients (N = 493) in a 2:1 ratio. Secondary objectives were objective response rate, pharmacokinetics, safety, and health-related quality of life. The median PFS in the abemaciclib and placebo groups was 29.1 months and 14.9 months, respectively.1 Abemaciclib plus a nonsteroidal aromatase inhibitor was a successful initial treatment in the Japanese subpopulation, with a tolerable safety profile, consistent with findings in the whole population.1

Continuous abemaciclib dosage with an aromatase inhibitor provided significant clinical benefit to postmenopausal women with HR-positive, HER2-negative advanced breast cancer in the MONARCH 3 trial.2 The development and approval of cyclin-dependent kinase (CDK)4/6 inhibitors for HR-positive, HER2-negative, advanced breast cancer has changed the treatment paradigm by significantly extending PFS and overall survival.2 Abemaciclib is the only CDK4/6 inhibitor currently licensed for the treatment of patients with HR-positive, HER2-negative, advanced breast cancer on a continuous dosage regimen as monotherapy in the United States or in combination with fulvestrant or a nonsteroidal aromatase inhibitor or an aromatase inhibitor.2

Abemaciclib given as an oral continuous schedule showed efficacy and tolerability as monotherapy and in combination with fulvestrant in patients with HR-positive, HER2-negative metastatic breast cancer.3 Abemaciclib had an acceptable safety profile and was an effective first-line treatment for patients with HR-positive, HER2-negative advanced breast cancer, improving PFS and objective response rate substantially.3

References

  1. Takahashi M, Tokunaga E, Mori J, et al. Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Breast Cancer. 2021 Oct 18. Epub ahead of print.
  2. Johnston S, O’Shaughnessy J, Martin M, et al. Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups. NPJ Breast Cancer. 2021;7:80.
  3. Di Leo A, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer. Ann Oncol. 2017;28(suppl 5):V609.
Related Items
The Pharmacist and Patients With HER2-Positive or HER2-Low Metastatic Breast Cancer: Navigating the Treatment Landscape
The Pharmacist and Patients With HER2-Positive or HER2-Low Metastatic Breast Cancer: Navigating the Treatment Landscape published on January 11, 2024 in Breast Cancer
Ovarian Function Suppression in Premenopausal Women with HR+ Breast Cancer
Emily M. Beard, RN, BSN, OCN, CBCN, Abbey J. Kaler, MS, APRN, FNP-C, Mohammed A. Jaloudi, MD
Best Practices in Ovarian Function Suppression in Breast Cancer published on December 21, 2023 in Breast Cancer
Enhertu Received Regular FDA Approval for Patients with Unresectable or Metastatic Breast Cancer
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Breast Cancer
Pembrolizumab plus Chemotherapy for Neoadjuvant and Adjuvant Therapy in Early Triple-Negative Breast Cancer: KEYNOTE-522
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in From the Literature, Breast Cancer, Checkpoint Inhibitors
Lynparza Receives FDA Approval for Adjuvant Treatment of High-Risk Early Breast Cancer with BRCA Mutation
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update, Breast Cancer
Evaluating Adverse Events in Patients with Breast Cancer and HIV Infection Receiving Concomitant Antiretroviral Therapy and Chemotherapy with Curative Intent
Donyika Joseph, PharmD, BCOP, Farnaz Foolad, PharmD, BCPS, Neelam K. Patel, PharmD, BCOP, Meghan Karuturi, MD, MSc, Jaime Kaushik, PharmD, BCOP
JHOP - April 2022 Vol 12, No 2 published on May 2, 2022 in Original Article, Adverse Events, Breast Cancer, Infections
Advances in Breast Cancer Treatments: Are We Extending Patients’ Survival?
Meg Barbor, MPH
JHOP - June 2019 Vol 9, No 2 published on April 28, 2022 in HOPA Highlights, Breast Cancer
Development and Implementation of a Pharmacist-Led Virtual Clinic Improve the Management of Patients with Metastatic Breast Cancer Receiving CDK4/6 Inhibitors
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Time to Treatment Initiation and Outcomes for Patients with Nonmetastatic Breast Cancer Before and During the COVID-19 Pandemic at Community Cancer Centers
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Spontaneous Tumor Lysis Syndrome in a Patient with Stage IV HER2-Positive Breast Cancer: Case Report
Blake T. Robbins, PharmD, MBA , Alexander M. Kreimer, PharmD, BCPS , Reema A. Patel, MD, Allison R. Butts, PharmD, BCOP
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in Case Reports, Tumor Lysis Syndrome, Breast Cancer
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: